SARS-CoV-2 Variant ValuPanel™ assays consist of separately delivered probes and primers that are designed for qualitative detection of specific SARS-CoV-2 mutations by genotyping using reverse transcription-polymerase chain reaction (RT-PCR). Each SARS-CoV-2 Variant ValuPanel consists of 2 BHQplus™ Probes and 2 primers for amplification and simultaneous discrimination between a specific mutation and the wild-type SARS-CoV-2 sequence.
For Research Use Only. Not for use in diagnostic procedures.
- Reliable results: From the trusted inventor of Black Hole Quencher™ (BHQ™) technology referenced in 7 of 8 WHO COVID-19 protocols
- High specificity: Enhanced affinity of the BHQplus Probe technology delivers high-fidelity genotyping results
- Flexible assay design: Increased assay design options with separately delivered probes and primers
- Consistent quality: All probes and primers are HPLC purified and are manufactured and shipped from a facility entirely separate from positive control production.
Several variants of SARS-CoV-2 have emerged bringing challenges to diagnostic tests and pandemic eradication efforts. Of particular significance are variants B.1.1.7 (also known as Alpha, first identified in the United Kingdom), B.1.351 (also known as Beta, first identified in South Africa), B.1.1.28 (also known as P.1 or Gamma, first identified in travelers from Brazil who arrived in Japan) and B.1.617 (including the Kappa and Delta variants, first identified in India). The ability to quickly and reliably identify SARS-CoV-2 mutations will enhance the ability to gather crucial public health information regarding transmissibility kinetics of new variants, and the efficacy of vaccines and therapeutics.
|ValuPanel||SARS-CoV-2 Mutation||Variants containing specified SARS-CoV-2 mutation||Availability|
|Pango lineage||WHO label|
|SARS-CoV-2 Variant ValuPanel [E484K]||E484K||B.1.351, B.1.1.28 (P.1), B1.525||Beta, Gamma, Eta||Order now|
|SARS-CoV-2 Variant ValuPanel [del H69-V70]||ΔH69-V70||B.1.1.7, B.1.525, B.1.1.298 (DK mink Cluster V)||Alpha, Eta|
|SARS-CoV-2 Variant ValuPanel [N501Y]||N501Y||B.1.1.7, B.1.351, B.1.1.28 (P.1)||Alpha, Beta, Gamma|
|SARS-CoV-2 Variant ValuPanel [K417N]||K417N||B.1.351||Beta|
|SARS-CoV-2 Variant ValuPanel [K417T]||K417T||B.1.1.28 (P.1)||Gamma|
|SARS-CoV-2 Variant ValuPanel [P681H] (Version 2)*||P681H||B.1.1.7||Alpha|
|SARS-CoV-2 Variant ValuPanel [L452R]||L452R||B.1.427, B.1.429, B.1.617.1, B.1.617.2||Epsilon, Kappa, Delta|
|SARS-CoV-2 Variant ValuPanel [P681R]||P681R||B.1.617.1, B.1.617.2, B.1.617.3||Kappa, Delta|
|SARS-CoV-2 Variant ValuPanel [E484Q]||E484Q||B1.617.1, B1.617.3||Kappa|
*Please note: We replaced the first version of the P681H assay (Cat. No. SCV-P681H-1000) with SARS-CoV-2 Variant ValuPanel [P681H] (Version 2), which was designed to avoid the potential proximal mutation at Q677 and demonstrates improved cluster separation in endpoint genotyping analysis.
Amino acid mutations present in SARS-CoV-2 variants.
|Spike protein mutation||B1.1.7(Alpha)||B.1.351(Beta)||P.1 (Gamma)||B1.617.1(Kappa)||B1.617.2(Delta)||B1.617.3||B.1.427/9(Epsilon)|